A pharmaceutical composition for treating gynecological inflammation, its preparation method and application

A technology for gynecological inflammation and composition is applied in the field of pharmaceutical composition for treating gynecological inflammation and its preparation field, which can solve the problems of short drug residence time, poor drug absorption effect, influence on the normal function of skin and mucous membranes, etc., and improve the anti-infective treatment effect. , to solve the narrow therapeutic range, the effect of excellent pharmaceutical properties

Active Publication Date: 2019-04-23
MUDANJIANG MEDICAL UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In addition, the existing therapeutic drugs for gynecological inflammation mainly include suppository, ointment, effervescent tablet, etc., but there is a problem that the therapeutic effect is not good enough. , affect the normal function of the skin and mucous membrane, and the contact surface with the mucous membrane is small, and the effective residence time in the vagina is short, thus affecting the curative effect; Short time, poor drug absorption

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical composition for treating gynecological inflammation, its preparation method and application
  • A pharmaceutical composition for treating gynecological inflammation, its preparation method and application
  • A pharmaceutical composition for treating gynecological inflammation, its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0057] Example group: ciclopirox olamine / palatin / clindamycin compound gel (weight ratio 1: 1: 1, drug concentration 0.25-1%), ciclopirox olamine / palatin / secnitrate Azole compound gel (weight ratio 1:1:1, drug concentration 0.25-1%), 1%-high dose group, 0.5%-middle dose group, 0.25%-low dose group.

[0058] Control group: a single drug group including ciclopirox olamine, palmatine, clindamycin, and secnidazole, a positive drug group of Shuangzotai suppository, the drug concentration is 1%, and the blank control group uses excipients.

[0059] General preparation method of gel:

[0060] a) The active ingredients of the medicine are mixed according to the weight ratio, then pulverized, and sieved for subsequent use;

[0061] b) Add 20g of glycerin, 4g of polyethylene glycol, and 0.8g of chitosan to the crushed medicine prepared in step a, stir and mix evenly to obtain a mixture for subsequent use;

[0062] c) Mix 2g of carbomer with 60-80% of the total amount of purified water,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to a pharmaceutical composition for treating gynecologic inflammations. The pharmaceutical composition comprises ciclopirox olamine, palmatine and clindamycin or secnidazole serving as active pharmaceutical ingredients, wherein a synergistic effect is achieved among the three active pharmaceutical ingredients. The preferable preparation form of the pharmaceutical composition is gel. The product is uniform, fine and smooth in texture and appropriate in thickness. The pharmaceutical composition can be used for effectively treating mixed infectious diseases, particularly mixed infective vaginitis.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for treating gynecological inflammation, a preparation method and application thereof. Background technique [0002] Gynecological inflammation mainly refers to a series of infectious or non-infectious inflammations in the female reproductive system. The most common gynecological inflammation includes vaginitis. The main symptoms are vulva and vaginal itching, redness, pain, and increased leucorrhea. Recurrence after the onset seriously affects women's work and sleep, endangering their physical and mental health. [0003] Gynecological inflammation problems are mainly caused by four kinds of problems, namely: bacterial, fungal, trichomonas and viral infections. Mixed infectious vaginitis is the most common vaginitis, and the prevalence rate is as high as 70% in areas with poor sanitation. Staphylococcus aureus, Escherichia coli, Candida...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4412A61K31/4375A61K31/7056A61K31/4164A61K47/36A61K9/06A61P15/02A61P31/04A61P31/10A61P33/02
CPCA61K9/0034A61K9/06A61K31/4164A61K31/4375A61K31/4412A61K31/7056A61K47/36A61K2300/00
Inventor 陈佳权马莉宫玉凤于涛
Owner MUDANJIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap